NMNAT3

Nicotinamide mononucleotide adenylyltransferase 3 (NMNAT3) is an enzyme that in humans is encoded by the NMNAT3 gene.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 2 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Nicotinamide mononucleotide adenylyltransferase 3 (NMNAT3) is an enzyme that in humans is encoded by the NMNAT3 gene. NMNAT3 is the third of three protein isoforms of nicotinamide-nucleotide adenylyltransferase (NMNAT) found in humans. As with the other NMNATs, NMNAT3 is an enzyme that catalyzes nicotinamide adenine dinucleotide (NAD) synthesis.

NMNAT3 levels are highest in liver, heart, skeletal muscle, and erythrocytes. NMNAT3 is localized in mitochondria or cytoplasm, depending upon the cell type. Knockdown of NMNAT3 gene expression in cell culture strongly reduces mitochondrial function.

NMNAT3 is essential for maintaining NAD in red blood cells. The catechin epigallocatechin gallate found in tea can activate NMNAT3 by more than 40%. Until January 2026, mutations in the NMNAT3 gene had not been associated with any known human disease, although it had been discovered that NMNAT3 deficiency causes hemolytic anemia in mice.

In January 2026, researchers at the University Medical Center Utrecht in Utrecht, The Netherlands, were the first to link NMNAT3 deficiency to disease in vivo, in a patient with unexplained hereditary hemolytic anemia. The patient was successfully treated by supplementing NAD.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1378680488 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

No external citation was extracted for this revision. That is a statement about the source, not a claim that none exists.